Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA).

We tried to develop a dual-modal PET/MR imaging probe using a straightforward one-pot method by encapsulation with specific amphiphiles. In this study, iron oxide (IO) nanoparticles were encapsulated with three amphiphiles containing PEG, DOTA and the prostate-specific membrane antigen (PSMA)-targeting ligand in aqueous medium.

The diameter of the prepared nanoparticle DOTA-IO-GUL was 11. 01 ± 1. 54 nm. DOTA-IO-GUL was labeled with (68)Ga in high efficiency. The DOTA-IO-GUL showed a dose-dependent binding to LNCaP (PSMA positive) cells via a competitive binding study against (125)I-labeled MIP-1072 (PSMA-targeting agent). Additionally, PET and MR imaging results showed PSMA selective uptake by only 22Rv1 (PSMA positive) but not PC-3 (PSMA negative) in dual-tumor xenograft mouse model study. MR imaging showed high resolution, and PET imaging enabled quantification and confirmation of the specificity. In conclusion, we have successfully developed the specific PSMA-targeting IO nanoparticle, DOTA-IO-GUL, as a dual-modality probe for complementary PET/MR imaging.

Nanomedicine : nanotechnology, biology, and medicine. 2015 Dec 28 [Epub ahead of print]

Sung-Hyun Moon, Bo Yeun Yang, Young Ju Kim, Mee Kyung Hong, Yun-Sang Lee, Dong Soo Lee, June-Key Chung, Jae Min Jeong

Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Department of Radiation Applied Life Science, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Department of Radiation Applied Life Science, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. , Department of Nuclear Medicine and Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea; Department of Radiation Applied Life Science, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.  

PubMed